Aromatase Inhibitors for Breast Cancer: Proven Efficacy Across the Spectrum of Disease
- 1 February 2008
- journal article
- review article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 8 (1), 50-64
- https://doi.org/10.3816/cbc.2008.n.003
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?British Journal of Cancer, 2006
- Effects of third-generation aromatase inhibitors on boneEuropean Journal Of Cancer, 2006
- Long-term risk of breast cancer recurrence: the need for extended adjuvant therapyZeitschrift für Krebsforschung und Klinische Onkologie, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- An open randomised trial of second-line endocrine therapy in advanced breast cancerEuropean Journal Of Cancer, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *European Journal Of Cancer, 1996